EAGLEVILLE, PA, January 29, 2016–Streamlight ® Inc., a leading provider of high-performance lighting and weapon light/laser sighting devices, has expanded its ProTac ® family with two new gun-mounted ...
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors ...
Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
NEW HAVEN, Conn., April 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...
Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...
The HIV-1 Nef accessory factor promotes viral replication and immune escape of HIV-infected cells, making it an attractive drug target. Our team previously identified small molecules that bind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results